DISCOVERY & DEVELOPMENT
THERAPEUTICS PLATFORM
We are making important advancements in medicine by harnessing the microbiome as a rich source of novel therapeutics...
THERAPEUTICS PLATFORM
APPROACH
"We aim to transform rigorous scientific insights into groundbreaking microbial products with clinical utility."
GenieBiome leverages one of the first and largest Asian human microbial data-driven approaches to therapeutic discoveries. Our expanding disease-specific microbial datasets in contrast with a comprehensive control dataset delivers a rich source of novel therapeutic candidates. We have exceptional ability to achieve accurate species, functional profiles, and metabolic-pathway analysis.
Our Targeted Microbiome Supplements were derived utilizing large metagenomic microbial datasets and machine-learning approaches to deliver missing microbes and their biologically important functions to correct “dysbiosis” in conditions associated with it.
Our Multi-functional Live Biotherapeutics uses a unique patented approach to isolate novel health-relevant bacteria and disease-specific bacterial isolates/metabolites for pre-clinical experiments with rapid development into effective biotherapeutics for treatment of human diseases.
THERAPEUTICS PLATFORM
GenieBiome (Therapeutics) launched G-NiiB Immunity product, a microbiome precision formula that improves immunity against Coronavirus (COVID)-19 and other respiratory infections tailored to Asians.
Rejuvenate Your Unique Microbiome
Boosting Your Immunity
G-NiiB Immunity Plus and G-NiiB Immunity Pro are unique microbiome Immunity formulas that can be used as dietary supplements. This formula uses big microbial datasets of over 1000 healthy individuals to select naturally-occurring prevalent live bacteria, in contrast with microbial profile of individuals with COVID-19. It utilizes patented microencapsulated technology from Italy to enhance live bacteria survival and delivery to the colon. Pilot data showed that it is associated with higher antibody response and less adverse effects following COVID-19 vaccine. It is clinically shown to be effective and safe in patients with local novel virus infection.
G-NiiB obtained exclusive patent# licensing from the Chinese University of Hong Kong.
For more information about G-NiiB Immunity product, please click here
THERAPEUTICS PLATFORM
PIPELINE
Leveraging on GenieBiome's large human metagenomic datasets, we are developing a pipeline of microbiome therapeutics targeting gastrointestinal diseases and conditions that extend beyond the gut, with several candidates for autism spectrum disorder, eczema, obesity/metabolic diseases, and non-alcoholic fatty liver disease in pre-clinical development. The content of our pipeline will change over time as new projects progress from research to development and from development to the market.
Brand names are trademarks either owned by and/or licensed to GenieBiome Limited or associated companies.
We have patented over 20 novel bacteria species that are currently undergoing pre-clinical testing for different diseases.
Targeted Microbiome Supplements:
We have developed new microbiome precision formulas for enhancing immunity separately tailored for adults (G-NiiB-Immunity plus) and children, or entirely personalized to reduce disease-related bacteria markers (G-NiiB Ultra-0301 for Colorectal cancer). GenieBiome also intends to partner with food technology companies to make our novel microbiome delivery system commercially available.
Multi-functional Live Biotherapeutics:
We are developing a novel class of orally administered multifunctional consortia of bacteria with the potential to restore microbiome functionality and resolve specific diseases. We use data from clinical studies of fecal transplant to discover microbes and their metabolites that can be targeted to treat diseases. We are harnessing defined consortia, or collections, of bacteria to modulate microbiome function.
UPCOMING PRODUCTS
G-NiiB-Ultra-0301 for CRC:
Microbiome precision targeting anti-CRC effects - Utilising deep-sequencing datasets of >600 subjects with CRC and healthy individuals, 3 unique bacteria consortia were identified to be depleted in subjects with CRC. Ultra-0301 was designed to replace these beneficial bacteria species leading to a significant reduction of CRC-related bacteria markers including Fusobacterium nucleatum (Fn).
G-NiiB Immunity infant:
Using metagenomic datasets of infant microbiome profiles and machine-learning analysis, we develop a formula containing 3 immunity-enhancing bacteria consortia, 2 prebiotics, and 2 metabolites approved for use in infants.
Discovery Project
Pre-Clinical
Phase I
Phase II
Phase III
Registration
